The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer
- Authors:
- S. Hilman
- PK. Koh
- S. Collins
- R. Allerton
View Affiliations
Affiliations:
Weston General Hospital, Somerset, UK. serena.hilman@waht.swest.nhs.uk
- Published online on: January 1, 2010 https://doi.org/10.3892/ol_00000038
-
Pages:
209-213
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The combination of treosulfan and gemcitabine (TG) has been shown to have activity in ovarian cancer. These two agents are thought to be synergistic, with gemcitabine causing the persistence of treosulfan-induced DNA crosslinks. This study aimed to investigate the response rates, survival and toxicity in patients with platinum-resistant ovarian cancer treated with TG. A retrospective case note review of the patients treated with TG was performed in one cancer centre between May 1st, 2000 and November 1st, 2005. Estimates of cumulative survival were obtained using the Kaplan-Meier method. Forty-nine patients were identified; median age at diagnosis was 55 years (range, 31-72) and the median follow-up was 45.1 months (range, 12.2-118.3). TG was used as second-, third-, fourth- and fifth-line chemotherapy in 15, 19, 13 and 2 patients, respectively. Fifteen patients (30.6%) had stable disease; 25 (51%), a partial response; 1 (2%), a complete response and 8 (16.3%) had progressive disease. Median survival following diagnosis was 45.1 months and the median relapse-free survival was 12 months. The median survival time from the start of TG was 13.7 months with a relapse-free survival of 6.3 months. The median number of cycles given was 7. The most common toxicity recorded was myelosuppression. There were no treatment-related deaths. TG chemotherapy produced favourable response rates in a heavily pre-treated group of patients with platinum-resistant epithelial ovarian cancer. This doublet warrants further investigation in a phase III trial setting.
View References
|
1
|
UK ovarian cancer statistics. 2008, Cancer
Research UK website.
|
|
2
|
De Vita. Treosulfan and gemcitabine in
heavily pretreated patients with breast and ovarian cancer:
laboratory study and clinical pilot trial of the ISCO clinical
study group. 7th edition. pp. 13642005
|
|
3
|
Fennelly J: Treosulfan
(Dihydroxybusulphan) in the management of ovarian carcinoma. Br J
Obstet Gynecol. 84:300–303. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Corrie PG, Shaw J, Spanswick VJ, et al:
Phase I trial combining gemcitabine and treosulfan in advanced
cutaneous and uveal melanoma patients. Br J Cancer. 92:1997–2003.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kurbacher CM, Grecu OM, Stier U, et al:
ATP chemosensitivity testing in ovarian and breast cancer: early
clinical trials. Recent Results. Cancer Res. 161:221–230.
2003.PubMed/NCBI
|
|
6
|
Reed NS, Poole CJ, Coleman R, et al: A
randomised comparison of treosulfan and carboplatin in patients
with ovarian cancer: a study by the Scottish Gynaecological Cancer
Trials Group (SGCTG). Eur J Cancer. 42:179–185. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lorusso D, di Stefano A, Fanfani F and
Scambia G: Role of gemcitabine in ovarian cancer treatment. Ann
Oncol. 17:188–194. 2006. View Article : Google Scholar
|
|
8
|
Grecu OM, Kurbacher CM, Mallman P,
Bruckner HW and Cree IA: Treosulfan and gemcitabine in heavily
pre-treated patients with breast and ovarian cancer. Proc Am Soc
Clin Oncol. 20:abs. 2500. 2001.
|
|
9
|
Paclitaxel, pegylated liposomal
doxorubicin and topotecan in the treatment of advanced ovarian
cancer, relapsed disease. NICE guidance. 2005
|
|
10
|
Gordon AN, Tonda M, Sun S and Rackoff W:
Long-term survival advantage for women treated with pegylated
liposomal doxorubicin compared with topotecan in a phase 3
randomized study of recurrent and refractory epithelial ovarian
cancer. Gynecol Oncol. 95:1–8. 2004. View Article : Google Scholar
|
|
11
|
Peng LH, Chen X and Wu T: Topotecan for
ovarian cancer. Cochrane Database Syst Rev. Apr 16;2008.E-pub ahead
of print.
|
|
12
|
Breidenbach M, Rein DT, Schondorf T,
Schmidt T, Konig E, Valter M and Kurbacher CM: Hematological
side-effect profiles of individualised chemotherapy regimen for
recurrent ovarian cancer. Anticancer Drugs. 14:341–346. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pederson-Bjergaard J, Nissen NI, Sorensen
HM, et al: Acute non-lymphocytic leukaemia in patients with ovarian
cancer following long-term treatment with treosulfan
(dihydroxybusulfan). Cancer. 45:19–29. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cannistra SA, Matulonis UA, Penson RT, et
al: Phase II study of bevacizumab in patients with
platinum-resistant ovarian cancer or peritoneal serous cancer. J
Clin Oncol. 25:5180–5186. 2007. View Article : Google Scholar
|
|
15
|
Garcia AA, Hirte H, Fleming G, et al:
Phase II clinical trial of bevacizumab and low-dose metronomic oral
cyclophosphamide in recurrent ovarian cancer: a trial of the
California, Chicago and Princess Margaret Hospital phase II
consortia. J Clin Oncol. 26:76–82. 2008. View Article : Google Scholar : PubMed/NCBI
|
